Evidence map›Paper›PMID 34229896›Full record

Trial reportArchives of medical research2022

Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial.

Gholamreza Farnoosh, Mostafa Akbariqomi, Taleb Badri, Mahdi Bagheri, Morteza Izadi, Ali Saeedi-Boroujeni, Ehsan Rezaie, Hadi Esmaeili Gouvarchin Ghaleh, Hossein Aghamollaei, Mahdi Fasihi-Ramandi and 2 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Archives of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05318144 (Prognostic Value of Serum Melatonin as a Biomarker for the Determination of Severe COVID-19 Infection in Pregnant Women), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05318144 completednot on this map

Prognostic Value of Serum Melatonin as a Biomarker for the Determination of Severe COVID-19 Infection in Pregnant Women

Typeobservational_patient_registrySponsorNazan Yurtcu MDRan2021 to 2022Enrolled228ConditionsCOVID-19 Acute Respiratory Distress Syndrome, Pregnancy Related, Pregnancy Complications
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Gholamreza FarnooshApplied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mostafa AkbariqomiApplied Microbiology Research Center, Systems Biology and poisonings Institute, Baqiyatallah university of Medical Sciences, Tehran, Iran.
Taleb BadriNeuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mahdi BagheriHealth Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Morteza IzadiHealth Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ali Saeedi-BoroujeniDepartment of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Ehsan RezaieMolecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Hadi Esmaeili Gouvarchin GhalehApplied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Hossein AghamollaeiChemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mahdi Fasihi-RamandiMolecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Kazem HassanpourDepartment of Pediatric, School of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.
GholamHossein AlishiriChemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: ghalishiri@gmail.com.
Baqiyatallah University of Medical Sciences · IRAhvaz Jundishapur University of Medical Sciences · IRSabzevar University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMelatonin has been known as an anti-inflammatory agent and immune modulator that may address progressive pathophysiology of coronavirus disease 2019 (COVID-19). AIM OF THE STUDY: To evaluate the clinical efficacy of adjuvant, use of melatonin in patients with COVID-19.

methodsThis single-center, double-blind, randomized clinical trial included 74 hospitalized patients with confirmed mild to moderate COVID-19 at Baqiyatallah Hospital in Tehran, Iran, from April 25, 2020-June 5, 2020. Patients were randomly assigned in a 1:1 ratio to receive standard of care and standard of care plus melatonin at a dose of 3 mg three times daily for 14 d. Clinical characteristics, laboratory, and radiological findings were assessed and compared between two study groups at baseline and post-intervention. Safety and clinical outcomes were followed up for four weeks.

resultsA total of 24 patients in the intervention group and 20 patients in the control group completed the treatment. Compared with the control group, the clinical symptoms such as cough, dyspnea, and fatigue, as well as the level of CRP and the pulmonary involvement in the intervention group had significantly improved (p <0.05). The mean time of hospital discharge of patients and return to baseline health was significantly shorter in the intervention group compared to the control group (p <0.05). No deaths and adverse events were observed in both groups.

conclusionsAdjuvant use of melatonin has a potential to improve clinical symptoms of COVID-19 patients and contribute to a faster return of patients to baseline health.

Indexed as

COVID-19MelatoninDouble-Blind MethodHumansIranSARS-CoV-2Treatment OutcomeMelatoninAdjunctive therapyClinical trialCOVID-19Melatonin

Identifiers

PMID34229896
PMCPMC8220995
OpenAlexW3174508896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.